|
Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH).
|
Oct 2013
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
|
Aug 2012
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival
|
Dec 2014
|
Am J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes
|
Mar 2013
|
Am J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
Quality of life and physicians' perception in myelodysplastic syndromes
|
May 2012
|
Am J Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Costs and quality of life in patients with myelodysplastic syndromes.
|
Aug 2013
|
Am J Blood Res
|
myelodysplastic syndromes (MDS)
|
|
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
|
Jul 2020
|
Aging
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies
|
Jan 2013
|
Adv Exp Med Biol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
